Edition:
United Kingdom

Pacira Pharmaceuticals Inc (PCRX.OQ)

PCRX.OQ on NASDAQ Stock Exchange Global Select Market

36.15USD
20 Apr 2018
Change (% chg)

$0.70 (+1.97%)
Prev Close
$35.45
Open
$35.30
Day's High
$36.60
Day's Low
$35.20
Volume
130,856
Avg. Vol
254,927
52-wk High
$52.45
52-wk Low
$26.98

Select another date:

Wed, Feb 28 2018

BRIEF-Pacira Pharmaceuticals Reports Q4 GAAP EPS Of $0.11

* PACIRA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Pacira Says FDA ‍committee ‍Did Not Reach A Unanimous Decision For Exparel As A Nerve Block To Produce Regional Analgesia​

* PACIRA PHARMACEUTICALS STATEMENT ON FDA ADVISORY COMMITTEE FOR EXPAREL® FOR USE AS A NERVE BLOCK TO PRODUCE REGIONAL ANALGESIA

BRIEF-Pacira Pharmaceuticals Says FDA Advisory Committee To Review SNDA For Exparel

* PACIRA PHARMACEUTICALS STOCK TRADING HALTED; FDA ADVISORY COMMITTEE TO REVIEW SNDA FOR EXPAREL® AS A NERVE BLOCK FOR REGIONAL ANALGESIA Source text for Eikon: Further company coverage:

BRIEF-Pacira Pharma says FDA Posts Briefing Documents For Advisory Meeting Reviewing SNDA For Exparel

* PACIRA PHARMACEUTICALS INC - FDA POSTS BRIEFING DOCUMENTS FOR ADVISORY MEETING REVIEWING SNDA FOR EXPAREL AS A NERVE BLOCK FOR REGIONAL ANALGESIA

BRIEF-Wellstar And Pacira To Minimize Opioid Use Across Surgical Procedures

* WELLSTAR HEALTH SYSTEM AND PACIRA PHARMACEUTICALS ANNOUNCE PARTNERSHIP TO MINIMIZE OPIOID USE AND STANDARDIZE OUTCOMES ACROSS SURGICAL PROCEDURES Source text for Eikon: Further company coverage:

BRIEF-Pacira Pharmaceuticals Reports Preliminary 2017 Revenues Of $286.6 Million

* PACIRA PHARMACEUTICALS REPORTS PRELIMINARY 2017 REVENUES OF $286.6 MILLION

BRIEF-Pacira announces FDA advisory committee meeting to review sNDA for Exparel

* Pacira announces FDA advisory committee meeting to review sNDA for Exparel as a nerve block for regional analgesia

BRIEF-Pacira Pharmaceuticals reports Q3 non-gaap earnings per share $0.11

* Pacira Pharmaceuticals Inc reports third quarter 2017 financial results

BRIEF-Pacira Pharma to invest up to $25 million in Tela Bio

* Committed to invest up to $25 million in Tela Bio, a privately-held surgical reconstruction company​

Select another date: